{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:45:36Z","timestamp":1785422736405,"version":"3.56.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.meegid.2019.103968","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T12:03:15Z","timestamp":1563364995000},"page":"103968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Nucleic acid vaccines for hepatitis B and C virus"],"prefix":"10.1016","volume":"75","author":[{"given":"Samaneh","family":"Karimkhanilouyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-3159","authenticated-orcid":false,"given":"Saeid","family":"Ghorbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0005","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbrc.2005.06.185","article-title":"A C-terminal truncated hepatitis C virus core protein variant assembles in vitro into virus-like particles in the absence of structured nucleic acids","volume":"334","author":"Acosta-Rivero","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.meegid.2019.103968_bb0010","first-page":"gutjnl","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","author":"Allweiss","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","article-title":"Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial","volume":"16","author":"Alvarez-Lajonchere","year":"2009","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3748\/wjg.v20.i1.148","article-title":"HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin","volume":"20","author":"Amador-Canizares","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"115","key":"10.1016\/j.meegid.2019.103968_bb0025","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.meegid.2019.103968_bb0030","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.meegid.2019.103968_bb0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/genes9040207","article-title":"Gene therapy for chronic HBV\u2014can we eliminate cccDNA?","volume":"9","author":"Bloom","year":"2018","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.meegid.2019.103968_bb0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol. Ther."},{"issue":"16","key":"10.1016\/j.meegid.2019.103968_bb0045","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1128\/JVI.79.16.10514-10527.2005","article-title":"Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection","volume":"79","author":"Brooks","year":"2005","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.meegid.2019.103968_bb0050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin-10 determines viral clearance or persistence in vivo","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jgm.1407","article-title":"Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination","volume":"12","author":"Castellanos","year":"2010","journal-title":"J. Gene Med."},{"issue":"4","key":"10.1016\/j.meegid.2019.103968_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.apsb.2014.05.002","article-title":"Therapeutic strategies for a functional cure of chronic hepatitis B virus infection","volume":"4","author":"Chang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.meegid.2019.103968_bb0065","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.4049\/jimmunol.1001790","article-title":"Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3\/4A-specific T cells during therapeutic vaccination","volume":"186","author":"Chen","year":"2011","journal-title":"J. Immunol."},{"issue":"27","key":"10.1016\/j.meegid.2019.103968_bb0070","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4254\/wjh.v7.i27.2729","article-title":"Clinical significance of hepatitis B surface antigen mutants","volume":"7","author":"Coppola","year":"2015","journal-title":"World J. Hepatol."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00430-014-0378-6","article-title":"Mouse models for therapeutic vaccination against hepatitis B virus","volume":"204","author":"Dembek","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.meegid.2019.103968_bb0080","first-page":"205","article-title":"Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids","volume":"35","author":"Duenas-Carrera","year":"2002","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"44","key":"10.1016\/j.meegid.2019.103968_bb0085","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.3748\/wjg.v12.i44.7118","article-title":"Genetic vaccination with Flt3-L and GM-CSF as adjuvants: enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection","volume":"12","author":"Encke","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2014ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2014","journal-title":"Gut"},{"issue":"5934","key":"10.1016\/j.meegid.2019.103968_bb0095","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.1172815","article-title":"IL-21R on T cells is critical for sustained functionality and control of chronic viral infection","volume":"324","author":"Fr\u00f6hlich","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.meegid.2019.103968_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1743-422X-10-239","article-title":"Medical virology of hepatitis B: how it began and where we are now","volume":"10","author":"Gerlich","year":"2013","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00430-014-0373-y","article-title":"Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives","volume":"204","author":"Gerlich","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"issue":"42","key":"10.1016\/j.meegid.2019.103968_bb0110","doi-asserted-by":"crossref","first-page":"11984","DOI":"10.3748\/wjg.v21.i42.11984","article-title":"Progress in the development of vaccines for hepatitis C virus infection","volume":"21","author":"Ghasemi","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.meegid.2019.103968_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","article-title":"Host\u2013virus interactions in hepatitis B virus infection","volume":"36","author":"Guidotti","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0125","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","article-title":"A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2012.07.006","article-title":"Therapeutic vaccination against chronic hepatitis C virus infection","volume":"96","author":"Ip","year":"2012","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.meegid.2019.103968_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003490","article-title":"CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion","volume":"9","author":"Isogawa","year":"2013","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.meegid.2019.103968_bb0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/rmv.705","article-title":"Countering hepatitis B virus infection using RNAi: how far are we from the clinic?","volume":"21","author":"Ivacik","year":"2011","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.meegid.2019.103968_bb0155","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(11)60067-6","article-title":"65 a therapeutic vaccine for HCV based on novel, rare, adenoviral vectors","volume":"54","author":"Kelly","year":"2011","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00430-014-0379-5","article-title":"Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck","volume":"204","author":"Kosinska","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.meegid.2019.103968_bb0165","series-title":"Development of an mRNA Vaccination Strategy for the Prevention and Treatment of HBV Infection","author":"Lamb","year":"2017"},{"issue":"5","key":"10.1016\/j.meegid.2019.103968_bb0175","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.meegid.2019.103968_bb0180","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"44","key":"10.1016\/j.meegid.2019.103968_bb0185","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.3748\/wjg.v12.i44.7126","article-title":"Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models","volume":"12","author":"Li","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.meegid.2019.103968_bb0190","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.meegid.2019.103968_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. \u2013 Nucleic Acids"},{"issue":"6","key":"10.1016\/j.meegid.2019.103968_bb0200","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/13543784.16.6.787","article-title":"Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model","volume":"16","author":"Lu","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.meegid.2019.103968_bb0205","first-page":"e79","article-title":"Progress towards a hepatitis C virus vaccine","volume":"2","author":"Man John Law","year":"2013","journal-title":"Emerg. Microbes. Infect."},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2515\/therapie:2005033","article-title":"Therapeutic vaccination against chronic hepatitis B virus infection","volume":"60","author":"Mancini-Bourgine","year":"2005","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.meegid.2019.103968_bb0215","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","article-title":"Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"40","author":"Mancini-Bourgine","year":"2004","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.meegid.2019.103968_bb0220","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1016\/j.vaccine.2005.08.013","article-title":"Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers","volume":"24","author":"Mancini-Bourgine","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.meegid.2019.103968_bb0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virusres.2017.01.003","article-title":"Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus","volume":"244","author":"Moyo","year":"2018","journal-title":"Virus Res."},{"issue":"1\u20132","key":"10.1016\/j.meegid.2019.103968_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13337-015-0247-y","article-title":"Hepatitis B virus infection: an insight into infection outcomes and recent treatment options","volume":"26","author":"Noordeen","year":"2015","journal-title":"Virusdisease"},{"issue":"12","key":"10.1016\/j.meegid.2019.103968_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.meegid.2019.103968_bb0240","series-title":"Viral Regulatory Structures and Their Degeneracy","first-page":"71","article-title":"Transcriptional regulation of HIV","author":"Peterlin","year":"2018"},{"issue":"2","key":"10.1016\/j.meegid.2019.103968_bb0245","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.meegid.2019.103968_bb0250","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1084\/jem.20011723","article-title":"Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection","volume":"195","author":"Reignat","year":"2002","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.meegid.2019.103968_bb0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7196\/SAMJ.6452","article-title":"South African guideline for the management of chronic hepatitis B: 2013","volume":"103","author":"Spearman","year":"2013","journal-title":"S. Afr. Med. J."},{"issue":"10049","key":"10.1016\/j.meegid.2019.103968_bb0270","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"issue":"261","key":"10.1016\/j.meegid.2019.103968_bb0275","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.meegid.2019.103968_bb0280","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9959","key":"10.1016\/j.meegid.2019.103968_bb0285","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"issue":"42","key":"10.1016\/j.meegid.2019.103968_bb0290","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0295","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1742-4690-9-72","article-title":"Can immunotherapy be useful as a \u201cfunctional cure\u201d for infection with human immunodeficiency virus-1?","volume":"9","author":"Vanham","year":"2012","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0300","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","article-title":"Redefining chronic viral infection","volume":"138","author":"Virgin","year":"2009","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.meegid.2019.103968_bb0305","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jvh.12542","article-title":"Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC-targeting protein","volume":"23","author":"Wang","year":"2016","journal-title":"J. Viral Hepat."},{"issue":"9","key":"10.1016\/j.meegid.2019.103968_bb0310","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/mt.2013.119","article-title":"Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C","volume":"21","author":"Weiland","year":"2013","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.meegid.2019.103968_bb0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11684-014-0313-7","article-title":"Vaccine therapies for chronic hepatitis B: can we go further?","volume":"8","author":"Wen","year":"2014","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.meegid.2019.103968_bb0320","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1","volume":"126","author":"Werle\u2013Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.meegid.2019.103968_bb0325","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.meegid.2019.103968_bb0330","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","article-title":"Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study","volume":"13","author":"Yang","year":"2006","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.meegid.2019.103968_bb0335","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2893.2012.01589.x","article-title":"A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy","volume":"19","author":"Yang","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.meegid.2019.103968_bb0340","first-page":"80","article-title":"Long-term effect of lamivudine treatment in chronic hepatitis B virus infection","volume":"7","author":"Yao","year":"1999","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"10.1016\/j.meegid.2019.103968_bb0345","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.12530","article-title":"Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.meegid.2019.103968_bb0350","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1128\/CVI.00490-09","article-title":"The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB\/c mice","volume":"17","author":"Zhu","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"5","key":"10.1016\/j.meegid.2019.103968_bb0355","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos (t) ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134819301868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134819301868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:42:35Z","timestamp":1761576155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134819301868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":70,"alternative-id":["S1567134819301868"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2019.103968","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic acid vaccines for hepatitis B and C virus","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2019.103968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103968"}}